137 related articles for article (PubMed ID: 33044742)
41. Macrophages in T cell/histiocyte rich large B cell lymphoma strongly express metal-binding proteins and show a bi-activated phenotype.
Hartmann S; Tousseyn T; Döring C; Flüchter P; Hackstein H; Herreman A; Ponzoni M; de Wolf-Peeters C; Facchetti F; Gascoyne RD; Küppers R; Steidl C; Hansmann ML
Int J Cancer; 2013 Dec; 133(11):2609-18. PubMed ID: 23686423
[TBL] [Abstract][Full Text] [Related]
42. Molecular aspects of Moraxella catarrhalis pathogenesis.
de Vries SP; Bootsma HJ; Hays JP; Hermans PW
Microbiol Mol Biol Rev; 2009 Sep; 73(3):389-406, Table of Contents. PubMed ID: 19721084
[TBL] [Abstract][Full Text] [Related]
43. Role of FNA with core biopsy or cell block in patients with nodular lymphocyte-predominant Hodgkin lymphoma.
Gupta S; Long SR; Natkunam Y; Kong CS; Gupta NK; Gratzinger D
Cancer Cytopathol; 2020 Aug; 128(8):570-579. PubMed ID: 32343479
[TBL] [Abstract][Full Text] [Related]
44. Pitfalls in the Diagnosis of Nodular Lymphocyte Predominant Hodgkin Lymphoma: Variant Patterns, Borderlines and Mimics.
Younes S; Rojansky RB; Menke JR; Gratzinger D; Natkunam Y
Cancers (Basel); 2021 Jun; 13(12):. PubMed ID: 34208705
[TBL] [Abstract][Full Text] [Related]
45. J chain and myocyte enhancer factor 2B are useful in differentiating classical Hodgkin lymphoma from nodular lymphocyte predominant Hodgkin lymphoma and primary mediastinal large B-cell lymphoma.
Moore EM; Swerdlow SH; Gibson SE
Hum Pathol; 2017 Oct; 68():47-53. PubMed ID: 28851661
[TBL] [Abstract][Full Text] [Related]
46. Intraparotid classical and nodular lymphocyte-predominant Hodgkin lymphoma: pattern analysis with emphasis on associated lymphadenoma-like proliferations.
Agaimy A; Wild V; Märkl B; Wachter DL; Hartmann A; Rosenwald A; Ihrler S
Am J Surg Pathol; 2015 Sep; 39(9):1206-12. PubMed ID: 25929348
[TBL] [Abstract][Full Text] [Related]
47. Evolutionary clonal trajectories in nodular lymphocyte-predominant Hodgkin lymphoma with high risk of transformation.
Paschold L; Willscher E; Bein J; Vornanen M; Eichenauer DA; Simnica D; Thiele B; Wickenhauser C; Rosenwald A; Bernd HW; Klapper W; Feller AC; Ott G; Fend F; Hartmann S; Binder M
Haematologica; 2021 Oct; 106(10):2654-2666. PubMed ID: 33882641
[TBL] [Abstract][Full Text] [Related]
48. Virulence determinants of Moraxella catarrhalis: distribution and considerations for vaccine development.
Blakeway LV; Tan A; Peak IRA; Seib KL
Microbiology (Reading); 2017 Oct; 163(10):1371-1384. PubMed ID: 28893369
[TBL] [Abstract][Full Text] [Related]
49. Does functional imaging distinguish nodular lymphocyte-predominant hodgkin lymphoma from T-cell/histiocyte-rich large B-cell lymphoma?
Barber NA; Loberiza FR; Perry AM; Bast M; Holdeman KP; Esfahane AB; Weisenburger DD; Vose J; Bierman P; Armitage JO; Bociek RG
Clin Lymphoma Myeloma Leuk; 2013 Aug; 13(4):392-7. PubMed ID: 23773450
[TBL] [Abstract][Full Text] [Related]
50. Diagnosis and differential diagnosis of nodular lymphocyte-predominant Hodgkin's lymphoma.
Liu Y; Zhu X; Zhuang H; Lin H; Wu Q; Jiang G; Gu Y; Luo D; Luo X
Zhonghua Bing Li Xue Za Zhi; 2002 Jun; 31(3):227-30. PubMed ID: 12475440
[TBL] [Abstract][Full Text] [Related]
51. Nodular lymphocyte predominant hodgkin lymphoma: biology, diagnosis and treatment.
Goel A; Fan W; Patel AA; Devabhaktuni M; Grossbard ML
Clin Lymphoma Myeloma Leuk; 2014 Aug; 14(4):261-70. PubMed ID: 24650975
[TBL] [Abstract][Full Text] [Related]
52. Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) with CD30-positive lymphocyte-predominant (LP) cells.
Seliem RM; Ferry JA; Hasserjian RP; Harris NL; Zukerberg LR
J Hematop; 2011 Sep; 4(3):175. PubMed ID: 32288859
[TBL] [Abstract][Full Text] [Related]
53. A 20-year population-based study on the epidemiology, clinical features, treatment, and outcome of nodular lymphocyte predominant Hodgkin lymphoma.
Strobbe L; Valke LL; Diets IJ; van den Brand M; Aben K; Raemaekers JM; Hebeda KM; van Krieken JH
Ann Hematol; 2016 Feb; 95(3):417-23. PubMed ID: 26732883
[TBL] [Abstract][Full Text] [Related]
54. Biology, clinical course and management of nodular lymphocyte-predominant hodgkin lymphoma.
Nogová L; Rudiger T; Engert A
Hematology Am Soc Hematol Educ Program; 2006; ():266-72. PubMed ID: 17124071
[TBL] [Abstract][Full Text] [Related]
55. Characterization of variant patterns of nodular lymphocyte predominant hodgkin lymphoma with immunohistologic and clinical correlation.
Fan Z; Natkunam Y; Bair E; Tibshirani R; Warnke RA
Am J Surg Pathol; 2003 Oct; 27(10):1346-56. PubMed ID: 14508396
[TBL] [Abstract][Full Text] [Related]
56. How I treat nodular lymphocyte-predominant Hodgkin lymphoma.
Eichenauer DA; Engert A
Blood; 2020 Dec; 136(26):2987-2993. PubMed ID: 32877522
[TBL] [Abstract][Full Text] [Related]
57. Characterizing the immune microenvironment for nodular lymphocyte-predominant Hodgkin lymphoma.
Binkley MS
Br J Haematol; 2022 Nov; 199(3):310-312. PubMed ID: 35993185
[TBL] [Abstract][Full Text] [Related]
58. Nodular lymphocyte predominant Hodgkin lymphoma behaves as a distinct clinical entity with good outcome: evidence from 14-year follow-up in the West of Scotland Cancer Network.
Farrell K; McKay P; Leach M
Leuk Lymphoma; 2011 Oct; 52(10):1920-8. PubMed ID: 21663507
[TBL] [Abstract][Full Text] [Related]
59. CD57+ T-cells are a subpopulation of T-follicular helper cells in nodular lymphocyte predominant Hodgkin lymphoma.
Sattarzadeh A; Diepstra A; Rutgers B; van den Berg A; Visser L
Exp Hematol Oncol; 2015; 4():27. PubMed ID: 26380151
[TBL] [Abstract][Full Text] [Related]
60. Nodular lymphocyte-predominant Hodgkin lymphoma: cytopathologic correlates on fine-needle aspiration.
Subhawong AP; Ali SZ; Tatsas AD
Cancer Cytopathol; 2012 Aug; 120(4):254-60. PubMed ID: 22367911
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
